Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMP:
- Armata Gains FDA Fast Track for AP-SA02 Therapy
- Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors
- Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
- Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
- Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year